MP0712/212Pb x DLL3 Radio-DARPin Therapy: SCLC and neuroendocrine tumors
MP0712 is a radiopharmaceutical directed specifically against DLL3 (delta-like ligand 3), a validated target expressed in more than 85% of patients with small cell lung cancer (SCLC).
Despite recent advances in the treatment of SCLC, there is still a high unmet need for patients not responding or relapsing from bispecific T-cell engagers or antibody-drug conjugates (ADC).
MP0712 delivers the potent alpha-emitting therapeutic isotope 212Pb in a targeted manner to DLL3-expressing tumor cells, thereby killing tumor lesions and minimizing impact on healthy tissues. This powerful mode of action offers the potential to significantly improve treatment options for these patients.
MP0712 is being co-developed by Molecular Partners and our strategic partner Orano Med, a pioneer in targeted alpha therapy.
